Lung Cancer
Conference Coverage
‘Promising’ durvalumab results spark phase 3 trial in mesothelioma
Conference Coverage
Germline testing in advanced cancer can lead to targeted treatment
In a study of nearly 12,000 cancer patients, 7%-9% of patients had targetable germline alterations.
News
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
News
Low-dose erlotinib seems feasible for frail, elderly patients with NSCLC
The disease control rate was 90%, the median progression-free survival was 9.3 months, and few patients required treatment modifications.
News
FDA expands approval of atezolizumab in NSCLC
–s...
News
FDA approves chemo-free combo for lung cancer
Conference Coverage
ASCO goes ahead online, as conference center is used as hospital
News
FDA approves selpercatinib for lung and thyroid RET tumors
News
COVID-19 death rate was twice as high in cancer patients in NYC study
The overall case fatality rate was 28% for cancer patients with COVID-19 and 14% for noncancer COVID-19 patients.
News
Three months of COVID-19 may mean 80,000 missed cancer diagnoses
A backlog of 22 million canceled or postponed tests for five common cancers is expected by early June.